Medtech Stocks Gaining Momentum

Bank of America analysts see the potential for medtech stocks to continue gaining momentum as they appear less vulnerable to healthcare-related controversies tied to RFK Jr. headlines.

The recent developments have strengthened the sector, with medtech rebounding from historically low valuations to trade more in line with its 10-year average discount to the Tools sector.

In just two days, medtech's discount to Tools narrowed from 20% to 12%, indicating renewed investor interest.

However, BofA states that medtech is "not yet above" its long-term average discount relative to Tools and is still trading at a 10% discount to the S&P 500.

Historically, medtech enjoyed a 9% premium to the S&P 500 as recently as 2023, suggesting potential for further gains. Analysts observe that "depressed medtech valuations" and its recent underperformance leave room for "multiple expansion for the entire group."

While value-driven product stories could gain short-term benefits, BofA warns that external factors, like tariffs and foreign exchange impacts, could reemerge as headwinds within the next six months.

These risks may sustain a wider premium for quality growth names within the medtech sector, according to BofA. Despite challenges, growth prospects remain robust due to new product introductions. BofA notes, "Quality growth PEs may be at absolute highs vs history, but growth outlooks are higher."

The analysts highlight that medtech's market position has been strengthened by a "post-election quality growth rally" and reduced exposure to healthcare risks linked to RFK Jr.'s potential influence.

While uncertainties remain, BofA maintains a cautiously optimistic outlook on the sector, emphasizing its rebound potential and resilience against broader market pressures.